NASDAQ:MOLN - Molecular Partners Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $26.51
  • Forecasted Upside: 33.13 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$19.91
▼ -0.3 (-1.48%)

This chart shows the closing price for MOLN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Molecular Partners Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MOLN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MOLN

Analyst Price Target is $26.51
▲ +33.13% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Molecular Partners in the last 3 months. The average price target is $26.51, with a high forecast of $35.00 and a low forecast of $19.52. The average price target represents a 33.13% upside from the last price of $19.91.

This chart shows the closing price for MOLN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Molecular Partners.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/20/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/27/2021SVB LeerinkLower Price TargetOutperform$36.00 ➝ $35.00Low
8/10/2021Credit Suisse GroupReiterated RatingNeutralLow
8/9/2021HC WainwrightReiterated RatingBuy$25.00High
7/12/2021SVB LeerinkReiterated RatingOutperformLow
7/12/2021CowenInitiated CoverageOutperformLow
7/12/2021Royal Bank of CanadaSet Price TargetOutperform$19.52High
6/21/2021HC WainwrightReiterated RatingBuy$25.00Low
(Data available from 9/20/2016 forward)

News Sentiment Rating

0.37 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/24/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/22/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/22/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/21/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/20/2021

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Molecular Partners logo
Molecular Partners AG operates as a clinical-stage biopharmaceutical company. It is developing Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of wet age-related macular degeneration, as well as for diabetic macular edema; and MP0250 that binds and inhibit vascular endothelial growth factor and hepatocyte growth factor pathways, which restores clinical sensitivity to various standard-of-care therapies in multiple myeloma. The company is also developing MP0274 that is in Phase I clinical trials for HER2-positive solid tumors; MP0310, which is in Phase I clinical trials for immuno-oncology; MPO317, a tumor-localized immune agonist that activates immune cells in the tumor; and Peptide-MHC, a tumor-localized immune-cell agonist to attack tumors. It has strategic partnerships with Allergan, Inc. and Amgen SA; and collaboration with AGC Biologics to develop anti-COVID-19 DARPin program. Molecular Partners AG was founded in 2004 and is headquartered in Schlieren, Switzerland.
Read More

Today's Range

Now: $19.91
Low: $19.75
High: $20.71

50 Day Range

MA: $19.77
Low: $18.34
High: $21.00

52 Week Range

Now: $19.91
Low: $18.00
High: $21.33

Volume

6,300 shs

Average Volume

56,732 shs

Market Capitalization

$642.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Molecular Partners?

The following Wall Street sell-side analysts have issued reports on Molecular Partners in the last twelve months: Cowen Inc, Credit Suisse Group AG, HC Wainwright, Royal Bank of Canada, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for MOLN.

What is the current price target for Molecular Partners?

3 Wall Street analysts have set twelve-month price targets for Molecular Partners in the last year. Their average twelve-month price target is $26.51, suggesting a possible upside of 33.1%. SVB Leerink LLC has the highest price target set, predicting MOLN will reach $35.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $19.52 for Molecular Partners in the next year.
View the latest price targets for MOLN.

What is the current consensus analyst rating for Molecular Partners?

Molecular Partners currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MOLN will outperform the market and that investors should add to their positions of Molecular Partners.
View the latest ratings for MOLN.

What other companies compete with Molecular Partners?

How do I contact Molecular Partners' investor relations team?

The company's listed phone number is 41-44-755-7700. The official website for Molecular Partners is www.molecularpartners.com.